How the recent failure of Silicon Valley Bank leaves several companies with significant deposits stuck in the bank. Will regulators step in and save the day?
Oncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022Company remains on track...
After losing some value lately, a hammer chart pattern has been formed for Oncorus, Inc. (ONCR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions,...
-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 ...
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to...
Additional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Preclinical...
– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy Platform has the potential...
-Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a...